143 related articles for article (PubMed ID: 11068949)
21. The impact of hypoxia and its modification of the outcome of radiotherapy.
Horsman MR; Overgaard J
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i90-i98. PubMed ID: 26983987
[TBL] [Abstract][Full Text] [Related]
22. Raising hemoglobin: an opportunity for increasing survival?
Thomas GM
Oncology; 2002; 63 Suppl 2():19-28. PubMed ID: 12466641
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
Machtay M; Pajak TF; Suntharalingam M; Shenouda G; Hershock D; Stripp DC; Cmelak AJ; Schulsinger A; Fu KK;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1008-17. PubMed ID: 17716826
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.
Mantovani G; Ghiani M; Curreli L; Maccio A; Massa D; Succu G; Lai P; Massa E; Mudu MC; Astara G
Oncol Rep; 1999; 6(2):421-6. PubMed ID: 10023014
[TBL] [Abstract][Full Text] [Related]
25. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
26. Treatment resistance of solid tumors: role of hypoxia and anemia.
Vaupel P; Thews O; Hoeckel M
Med Oncol; 2001; 18(4):243-59. PubMed ID: 11918451
[TBL] [Abstract][Full Text] [Related]
27. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
28. rHuEPO and treatment outcomes: the clinical experience.
Hudis CA; Van Belle S; Chang J; Muenstedt K
Oncologist; 2004; 9 Suppl 5():55-69. PubMed ID: 15591423
[TBL] [Abstract][Full Text] [Related]
29. [Anemia and radiotherapy].
Pasquier D; Lartigau E
Bull Cancer; 2003 Apr; 90 Spec No():S152-7. PubMed ID: 12856427
[TBL] [Abstract][Full Text] [Related]
30. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
31. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome.
Brizel DM; Dodge RK; Clough RW; Dewhirst MW
Radiother Oncol; 1999 Nov; 53(2):113-7. PubMed ID: 10665787
[TBL] [Abstract][Full Text] [Related]
32. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Campos SM; Duh MS; Lefebvre P; Rosberg J
J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
[TBL] [Abstract][Full Text] [Related]
33. Effect of pretreatment anemia on treatment outcome of concurrent radiochemotherapy in patients with head and neck cancer.
Fortin A; Wang CS; Vigneault E
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):255-60. PubMed ID: 18632214
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?
Harrison L; Blackwell K
Oncologist; 2004; 9 Suppl 5():31-40. PubMed ID: 15591420
[TBL] [Abstract][Full Text] [Related]
35. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
[TBL] [Abstract][Full Text] [Related]
36. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
37. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
38. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
39. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
40. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa.
Shasha D; Cremieux P; Harrison L
J Natl Compr Canc Netw; 2004 Sep; 2(5):509-17. PubMed ID: 19780258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
